profit from every $100 of sales.
$0$100
Biomerica
$1.30-13.91% today
-48.4% in 1 year
1-year low $1.301-year high $2.88
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Biomerica sold, what it kept, and what it did with the cash.
Sales went from $18.9 million in 2022 to $5.31 million in 2025, with -$4.97 million of profit last year.
SalesProfit
Biomerica vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Biomerica | No profit yet | ||
 Boston Scientific | 22.1× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.5× · Expensive | ||
 Zimmer Biomet Holdings | 28.1× · Fair price |
AI analysis
An AI analyst reads Biomerica's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 19 | 5 | 5 | 5 | |
| 3 | 0 | 1 | 0 | |
| -5 | -7 | -6 | -5 | |
| -4 | -7 | -6 | -5 | |
| -5 | -7 | -6 | -5 | |
| -2.88 | -4.00 | -2.84 | -2.16 | |
| 15.8% | 8.4% | 11.3% | 9.4% | |
| -24.0% | -135.3% | -117.6% | -96.7% | |
| -24.0% | -133.7% | -110.4% | -93.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 11 | 14 | 9 | 6 |
| Cash | 6 | 10 | 4 | 2 |
| Total debt | 1 | 1 | 1 | 0 |
| Total liabilities | 3 | 3 | 3 | 2 |
| 8 | 12 | 7 | 4 | |
| 2 | 2 | 2 | 2 | |
| -36.9% | -44.6% | -68.2% | -88.9% | |
| -54.4% | -60.9% | -90.7% | -121.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -0 | -5 | -5 | -4 | |
| 0 | 0 | 0 | 0 | |
| -1 | -6 | -5 | -4 | |
| Dividends paid | – | – | – | – |
| 0 | 1 | 0 | – | |
| 1 | 1 | 1 | 0 |
Valuation
- –
- –
- –
- 2.0×
- 1.1×
- –
- –
- -64.9%
- -83.2%
- 0.0%
Profitability
- 9.4%
- -96.7%
- -93.6%
- -89.3%
- -152.5%
- -72.2%
- -98.1%
- -85.6%
- -161.4%
- 19.3%
Growth
- −34.5%
- –
- +29.2%
- –
- −33.8%
Financial health
- -0.4×
- 0.06
- 4.0%
- –
- 2.64
- 1.59
- 0.89
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 883
Bottom 3%of 870
Bottom 1%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 13, 2026 | -0.44 | -1.20 | +63.3% |
| Jan 14, 2026 | -0.45 | – | – |
| Oct 14, 2025 | 0.00 | – | – |
| Apr 14, 2025 | -0.48 | – | – |
| Jan 14, 2025 | -0.06 | – | – |
| Oct 15, 2024 | -0.08 | – | – |
| Apr 12, 2024 | -0.11 | – | – |
| Jan 16, 2024 | -0.09 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
51No pass
Philip Fisher
36No pass
Peter Lynch
28No pass
Joel Greenblatt
0No pass
Charlie Munger
36No pass
Terry Smith
28No pass
Questions about Biomerica
Is Biomerica a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Biomerica AI analysis
What does Biomerica do?
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. It is in Medical - Devices.
Does Biomerica pay a dividend?
No. Biomerica does not pay a dividend at the moment.
Is Biomerica stock halal?
No. Biomerica does not pass our halal screen: its cash and confirmed interest-bearing investments are 40% of its market value, at or above the 33% limit. How we check
How has Biomerica stock done over the past year?
Down 48.4% over the past twelve months, to $1.30. It traded between $1.30 and $2.88 and is 54.9% below its high.
Who are Biomerica's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Biomerica's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.